Green Innovation GmbH; Filing of Food Additive Petition (Animal Use)
Published Date: 11/26/2025
Proposed Rule
Summary
Green Innovation GmbH has asked the FDA to approve a new food additive called hydrolyzed lignin for use in animal feed. This additive would be safe for many animals like chickens, cows, pigs, and dogs, and can be added up to 1% of their food. The petition was filed in September 2025, and if approved, it could improve animal nutrition without extra cost to farmers.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
Petition to Allow New Animal Feed Additive
On September 26, 2025, Green Innovation GmbH filed a petition asking FDA to allow hydrolyzed lignin as a source of neutral detergent soluble fiber in feed for broiler chickens, laying hens, turkeys, growing swine, sows, lactating dairy cows, beef cattle, sheep, goats, salmonids, and adult dogs. The petition requests allowance of the additive at no more than 1% of the food by weight, which the petition also expresses as 10 kilograms per metric ton of food.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-21198 — Drawbridge Operation Regulation; Wishkah River, Aberdeen, WA
The Coast Guard plans to temporarily keep the Wishkah Street Bridge in Aberdeen, WA, closed to boats from September 1, 2026, to August 31, 2027, so the Washington State Department of Transportation can fix and upgrade it. This change mostly affects boaters who use the Wishkah River, but since the bridge rarely opens, the impact should be small. The public can share their thoughts by January 12, 2026.
Next: 2025-21308 — Claims Filing Date for Insured Mail
If you send insured mail, heads up! The Postal Service is changing the earliest day you can file a claim from 6 days back to 15 days after mailing, starting January 18, 2026. This means you’ll have to wait a bit longer before filing claims, but it’ll line up better with other mail services and bulk claims.